What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-08-13 compared with 2025-05-14 · 6 added, 43 removed, 17 unchanged (74% of the section changed)

OTHER INFORMATION

Annual Meeting of Stockholders Date

Board of Directors has set the date of our 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) for July 15, 2025.

The exact time and place of the 2025 Annual Meeting will be specified in our Notice of 2025 Annual Meeting and related proxy statement

for the 2025 Annual Meeting.

the date of the 2025 Annual Meeting will differ by more than 30 days from the anniversary date of our 2024 Annual Meeting of Stockholders,

the previously announced deadline for stockholder proposals for the 2025 Annual Meeting pursuant to Rule 14a-8 under the Exchange Act

is no longer applicable.

Under the new deadline set by the Company, any stockholder proposal intended to be included in our proxy materials

for the 2025 Annual Meeting pursuant to Exchange Act Rule 14a-8 must be mailed to:

Dermata Therapeutics, Inc., 3525 Del Mar Heights Rd.,

#322, San Diego, CA 92130, Attn.:

Corporate Secretary, on or before the close of business on May 22, 2025.

In addition to complying with

this deadline, stockholder proposals intended to be included in our proxy materials for the 2025 Annual Meeting must also comply with

all applicable SEC rules, including Exchange Act Rule 14a-8.

the date of the 2025 Annual Meeting will not be more than thirty (30) days before or more than seventy (70) days after the anniversary

date of our 2024 Annual Meeting of Stockholders, the previously announced deadline for stockholder proposals or nominations under our

bylaws for the 2025 Annual Meeting is still applicable.

Pursuant to the bylaws, the deadline for any stockholder proposal or nomination

other than pursuant to Exchange Act Rule 14a-8 for the 2025 Annual Meeting was on February 6, 2025.

addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other

than nominees approved by the Board of Directors must provide notice that sets forth the information required by Rule 14a-19 under the

Exchange Act.

10b5-1 Trading Plans

the fiscal quarter ended March 31, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of

the fiscal quarter ended June 30, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of

the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”

as each term is defined in Item 408(c) of Regulation S-K.

Form of January 2025 PIPE Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

Form of January 2025 PIPE Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

Form of January 2025 PIPE Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

of March 2025 New Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with

the SEC on March 28, 2025).

of March 2025 HCW Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with

the SEC on March 28, 2025).

Clinical Trial Collaboration Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 21, 2025)

Form of January 2025 PIPE Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

of March 2025 Inducement Letter (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed

with the SEC on March 28, 2025).

Certification

of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

Certification

of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

Certification

of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., dated July 30, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 30, 2025).

Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).

Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within

4 unchanged sentences

Furnished, not filed.

Indicates a management contract or compensation plan, contract or arrangement.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

1 unchanged sentence

Therapeutics, Inc.

August 13, 2025

and Chief Executive Officer

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information